
Liver cancer – HCC
Hepatocellular carcinoma
The global incidence of liver cancer is increasing, growing 3% per year in Asia and Europe, and around 1-2% in the United States
Identifying HCC patients at very early stage (stage 0) is a huge clinical unmet need
Current imaging diagnostics offer poor sensitivity for small lesions (1-2cm)
Median’s iBiopsy® HCC
Unrivalled AI/ML Software as Medical Device (SaMD) enabling very early HCC diagnosis with unprecedented performance
The only end-to-end AI/ML tech-based CADe/CADx SaMD for very early stage HCC
Indicated for the detection, localization, and characterization of small nodules below 2cm
Unprecedented sensitivity and specificity versus standard of care
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA
Additional indications

Lung cancer
Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)

Liver fibrosis
Liver fibrosis in non-alcoholic steatohepatitis (NASH)
Latest news

PRESS RELEASE
Median Technologies to participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with two presentations on iBiopsy®

PRESS RELEASE
Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

PRESS RELEASE
Median Technologies announces design completion of its iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance
